These actions involve class-wide security labeling improvements and new submit-promoting demands for all ER/LA opioid analgesics. FDA also responded to two citizen petitions regarding labeling of opioids.  , with the treatment method of moderate-to-extreme acute pain exactly where the usage

Article Under Review